The HLA-II immunopeptidome of SARS-CoV-2

SARS-CoV-2 的 HLA-II 免疫肽组

阅读:5
作者:Shira Weingarten-Gabbay ,Da-Yuan Chen ,Siranush Sarkizova ,Hannah B Taylor ,Matteo Gentili ,Gabrielle M Hernandez ,Leah R Pearlman ,Matthew R Bauer ,Charles M Rice ,Karl R Clauser ,Nir Hacohen ,Steven A Carr ,Jennifer G Abelin ,Mohsan Saeed ,Pardis C Sabeti

Abstract

Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames. Most HLA-II peptides colocalize with known CD4+ T cell epitopes in coronavirus disease 2019 patients, including 2 reported immunodominant regions in the SARS-CoV-2 membrane protein. Overall, our analyses show that HLA-I and HLA-II pathways target distinct viral proteins, with the structural proteins accounting for most of the HLA-II peptidome and nonstructural and noncanonical proteins accounting for the majority of the HLA-I peptidome. These findings highlight the need for a vaccine design that incorporates multiple viral elements harboring CD4+ and CD8+ T cell epitopes to maximize vaccine effectiveness. Keywords: CD4(+) T cell; CP: Immunology; CP: Microbiology; HLA-II; SARS-CoV-2; antigen processing and presentation; immunity; immunopeptidome; noncanonical protein; viral antigen.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。